Modification of cyclooxygenase and lipoxygenase activity with asteridae extracts and optionally boswellic acid
AssigneeShaklee Corporation
InventorsPeter X. Zhang, Michael T. Yatcilla
Life of this patent
Estimating the term…
Abstract
Extracts from plants in the Asteridae subfamily, such as Carthamus tinctorious, are effective to selectively inhibit COX-2 activity and/or enhance COX-1 activity. When Asteridae extracts are combined with boswellic acid, the combination exhibits a synergistic inhibitory effect on both COX-2 and LO. Such extracts and combinations are used in methods of selectively inhibiting COX-2, inhibiting LO, and/or enhancing COX-1 activity as well as in the methods of treating conditions that would respond favorably to any of these effects.
Claims91
A pharmaceutical composition, comprising:
- a pharmaceutical carrier;
- and
- an Asteridae extract from any portion of the plant other than the seeds, wherein the Asteridae extract is present in an amount effective to selectively inhibit COX-2 activity and/or enhance COX-1 activity.
A therapeutic agent, comprising:
- an Asteridae extract;
- and
- boswellic acid, wherein the Asteridae extract and boswellic acid are present in amounts that are effective to selectively inhibit COX-2 activity and/or to enhance COX-1 activity and to inhibit LO activity.
A therapeutic agent, comprising:
- a Carthamus tinctorious extract, wherein the Carthamus tinctorious extract is a freeze-dried, powdered, ethanol extract from a flower of the Carthamus tinctorious plant that was extracted at about 45° C. or below;
- and
- a Bosswellia serrata extract comprising about 40-90% boswellic acid, wherein about 5-15% of the boswellic acid is 3-O-acetyl-11-keto-β-boswellic acid, and wherein the Carthamus tinctorious extract and the Bosswellia serrata extract are present in amounts that are effective to selectively inhibit COX-2 activity and to inhibit LO activity.
A method for treating a COX-2/LO mediated condition in a subject, comprising administering to the subject a dose of a pharmaceutical composition comprising an Asteridae extract from any portion of the plant other than the seeds and a pharmaceutical carrier, wherein the dose is effective to selectively inhibit COX-2 activity and to treat the COX-2/LO mediated condition.
A method for treating a COX-2/LO mediated condition in a subject, comprising administering to the subject a combination of an Asteridae extract and boswellic acid, wherein the combination of the Asteridae extract and boswellic acid is effective to selectively inhibit COX-2 activity and to inhibit LO activity and is effective to treat the COX-2/LO mediated condition.
A method for treating a condition for which COX-1 enhancement is favorable, comprising administering to a subject with a condition for which COX-1 enhancement is favorable, or who is at demonstrated risk for the condition for which COX-1 enhancement is favorable, a dose of a therapeutic agent comprising an Asteridae extract, wherein the Asteridae extract is effective to enhance COX-1 activity and to treat the condition for which COX-1 enhancement is favorable.
Dependencies are inferred from the claim text.